SAN DIEGO, Calif. and ST. OUEN L'AUMONE, France, Dec. 4, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative testing and genetic analysis solutions, announced that Laboratoire Cerba has launched its validated noninvasive prenatal test (NIPT) to health care providers and their patients in France, Belgium, Luxembourg and portions of the Middle East and Africa. Laboratoire Cerba's test utilizes patented technology licensed from Sequenom to analyze the relative amounts of chromosomes 21, 18 and 13 in cell-free fetal DNA obtained from a maternal blood sample.
"We are excited that Laboratoire Cerba has been able to develop and validate a noninvasive prenatal test using our ground-breaking patented technology," said Dirk van den Boom, Executive Vice President, R&D and Chief Technical Officer, Sequenom, Inc. "This is a process that we are able to replicate with other laboratories around the world, and we look forward to continuing to establish meaningful partnerships and drive continued access to our patented technology internationally."
As part of the process of developing its test, Laboratoire Cerba performed its own blinded validation study to confirm the test's accuracy.
"We are pleased to now offer prenatal testing through our network with the use of Sequenom's patented technology," said Sylvie Cado, Chief Operating Officer of Laboratoire Cerba. "We are continuously trying to improve our service and offerings for patients and healthcare providers, and we believe our physician customers and the expectant families they work with will be thrilled to have access to this important information in an accurate, safe and efficient method."
Under the license from Sequenom, Laboratoire Cerba has the right to market its noninvasive test in multiple countries, including France, Luxembourg, Belgium, Lebanon, Morocco, Algeria, Tunisia, Libya, Senegal, Ivory Coast, Burkina Faso, and Cameroun. Laboratoire Cerba will process test samples at laboratory facilities in Paris and will also have the option to send samples to Sequenom Laboratories in the United States for testing.
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving health care through revolutionary genomic and genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostic markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.
About Laboratoire Cerba
Laboratoire Cerba is a leading European specialized laboratory based in France and ISO 15189 accredited. Since its inception in 1967, it offers private laboratories and public hospitals in more than 35 countries a broad range of specialty testing services, such as molecular biology testing, oncology testing, allergy testing, hormonology testing, infectious disease testing and diagnostic genetic testing and has developed a broadly recognized expertise in innovation for new tests.
It is the founding member of the Cerba European Lab Group, a leading European clinical pathology laboratory, providing routine and specialized clinical laboratory testing services primarily in France, Belgium and Luxembourg, and supporting pharmaceutical and biotechnology companies worldwide in the clinical trial phase of their drug development processes.
Through its Routine Lab and Specialized Testing operations, the Group offers a range of over 2.500 routine and specialty clinical tests used by doctors and medical institutions to diagnose, monitor and treat diseases. The Central Lab testing operations, which operated through the BARC subsidiaries, provide safety and efficacy testing services to pharmaceutical companies and contract research organizations worldwide in connection with drug development processes.
For more information concerning CERBA, please consult our Web site www.lab-cerba.com
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Sequenom's expectations regarding its ability to replicate processes similar to that which it established with Laboratoire Cerba with other laboratories around the world and to continue to establish partnerships and drive continued access to its patented technology internationally, Laboratoire Cerba's performance under the license from Sequenom and expectations regarding the effects, benefits, or impact of Laboratoire Cerba's commercial test launch on Sequenom and on patients and healthcare providers, and Sequenom's commitment to improving healthcare through revolutionary genetic analysis solutions, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with reliance upon the collaborative efforts of Laboratoire Cerba, Sequenom, and those parties' abilities to develop and commercialize new technologies and products, particularly new technologies such as prenatal and other diagnostics and laboratory developed tests, Sequenom's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, ongoing litigation including patent litigation, and other risks detailed from time to time in Sequenom, Inc.'s most recent Quarterly and Annual Reports on Securities and Exchange Commission Forms 10-Q and 10-K, respectively, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
SOURCE Sequenom, Inc.